CClinicalTrials.gg
CompletedNCT06381284Updated Mar 25, 2025

Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment

An observational study in Myasthenia Gravis, Neuromuscular Manifestations and Neuromuscular Diseases, sponsored by ZS Associates. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by ZS Associates · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
215
Ages
18 Years and older
Sex
All
01

Study summary

This is a fully remote, site-less, prospective, observational study enrolling adults in the United States (excluding U.S. territories) with undiagnosed neuromuscular symptoms. The main study objective is to evaluate the feasibility of a social media recruitment campaign tied to a participant reported symptom survey and self-administered physical assessment tool to influence undiagnosed participants to seek care for suspected Myasthenia Gravis (MG).

Read the detailed description

Participants with undiagnosed neuromuscular symptoms will be targeted via social media paid advertisements to recruit them to our study landing page (weblink: https://bit.ly/unearthrootcause). Two assessment tools were developed by the study team: the Impact of Daily Living (IDL) Survey and the MG Exercise Assessment. Both tools were designed using supporting literature, accepted guidelines, and a rigorous review via a panel of practicing neurologist key opinion leaders experienced in treating MG patients.

Adult participants who don't have specific diagnosed neurologic conditions will first be screened for eligibility based on the results of the IDL survey which will query participants on the presence or absence of habits/symptoms characteristic of MG. Those who qualify will complete the MG Exercise Assessment in which participants are provided video instructions to perform a series of 10 physical tests to examine if specific muscle groups undergo inducible fatigue. The results of the MG Exercise Assessment are reviewed by a neurologist to determine if participants would benefit further from an in-person neurologist evaluation for MG by a provider. Each participant is provided with a report of the neurologist's evaluation. Participants will be followed for 1 year through bimonthly communications to determine if and when they followed up with a clinician and if they received a confirmed diagnosis of myasthenia gravis.

02

Conditions studied

  • Myasthenia Gravis
  • Neuromuscular Manifestations
  • Neuromuscular Diseases

Keywords

  • Social Media
  • Myasthenia Gravis
03

In context

Myasthenia Gravis

324 studies on the registry are indexed under Myasthenia Gravis; 146 are open to participants now.

This study's enrollment of 215 is above the median of 140 across 104 observational studies indexed under Myasthenia Gravis.

Browse Myasthenia Gravis studies →

Lead sponsor

ZS Associates is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult participants who have undiagnosed neuromuscular symptoms

Inclusion criteria

  • Reside within the 50 states of the United States at the time of enrollment
  • Age 19 or older if reside in Nebraska or Alabama, Age 21 or older if reside in Mississippi, Age 18 years or older if reside in any other state
  • Active email account
  • Fluency in English (spoken / written), as demonstrated by the ability to read and sign the Informed Consent Form

Exclusion criteria

Exclusion Criteria:

  • Live in an overseas territory of the United States
  • Inability or unwillingness to provide written informed consent
  • Diagnosed myasthenia gravis
  • Diagnosed multiple sclerosis
  • Have speech impairment, eye/arm/leg weakness due to diagnosed brain cancer, or stroke
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
215 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants with undiagnosed neuromuscular symptoms

    Behavioral: Social media recruitment · Behavioral: Self-Assessment · Behavioral: Follow-up

Interventions

  • BehavioralSocial media recruitment

    Social media users exposed to a variety of paid social media advertisements as a recruitment tool for study enrollment

  • BehavioralSelf-Assessment

    Eligible participants are asked to complete self-administered physical tests to assess inducible fatigue of specific muscle groups

  • BehavioralFollow-up

    Patients triaged based on their assessed risk of MG are asked to complete recommended follow-up with a clinician to determine presence of myasthenia gravis

06

What researchers measure

Primary outcomes

  1. Social media recruitment feasibility

    Measure the engagement and feasibility metrics of the social media campaign

    Time frame: Enrollment period (4-6weeks)

Secondary outcomes

  1. MG Exercise Assessment Tool validity

    Estimate preliminary measures of validity for the MG Exercise Assessment Tool

    Time frame: 1 year from time of enrollment

Other outcomes

  1. Time to diagnosis

    Evaluate the time to diagnosis for any participant who has a confirmed diagnosis of MG after the completion of the study compared to that reported in literature

    Time frame: 1 year from time of enrollment

07

Study locations

1 site
  • ZS Associates
    Evanston, Illinois 60201, United States
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06381284
Lead sponsor
ZS Associates
Collaborators
UCB Pharma, University of California, San Francisco
Responsible party
Ananda Vishnu Pandurangadu, MD (Senior Consultant, ZS Associates) — Principal investigator
First posted
Apr 24, 2024
Start date
Mar 28, 2024
Primary completion
Mar 3, 2025
Completion
Mar 3, 2025
Last update
Mar 25, 2025

Study contacts

Ananda Vishnu Pandurangadu, MD
principal investigator · ZS Associates

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion